DaVita Clinical Research Presents “Catheter Reduction Reduces Hospitalization and Mortality” Poster Amongst 56 Others at t

MINNEAPOLIS--(BUSINESS WIRE)-- DaVita Clinical Research® (DCR®), a provider of clinical research and diagnostic laboratory services, announced today that 56 posters and five oral presentations will be presented by the Company’s unsurpassed renal experts at the 43rd American Society of Nephrology (ASN) Annual Meeting and Scientific Exposition from November 16 - 21, 2010, at the Colorado Convention Center located in Denver, Colorado.

In DCR’s presentation titled, “Catheter Reduction Reduces Hospitalization and Mortality,” experts will discuss that following an aggressive catheter reduction initiative, such as the DaVita Cathaway™ program, decreases both central venous catheter (CVC) incidence and duration associated with significant decreased morbidity and mortality.

The DaVita® network, including DaVita, Inc., DCR, and its renal-focused counterparts and partners were selected to represent a total of 56 posters and deliver five oral presentations. These numbers represent a notable presence by DaVita and the Company’s related entities at ASN. While key abstracts are listed below, all represent impactful research showing great depth and presence at the meeting, as well as thought leadership.

The Effect of Sodium Thiosulfate (STS) on Measures of Mineral and Bone Disorders. Tracy J. Mayne, Tasos Constantin, Carey Colson, Mahesh Krishnan. DaVita, Inc. TH-PO132

The Effect of Pre-ESRD Care on Incident Patient Outcomes. Joe Weldon, Karen Spach, Mahesh Krishnan. DaVita, Inc. TH-PO451

Evaluating the Impact of Change in Pre-Dialysis Weight on a Change in Measured Hemoglobin. Joe Weldon, Tracy J. Mayne, Steve Wilson, Mahesh Krishnan. DaVita, Inc. TH-PO469

Determinants and Predictors of Successful Home Hemodialysis Training in a Multi-center US Observational Cohort. Christopher T. Chan, John Moran. Toronto General Hospital and DaVita, Inc. TH-FC125

Medication Non-Adherence Predicts Hospitalization Rate and Healthcare Costs in Hemodialysis (HD) Patients. Harold Manley, Steven Wang, Allen R. Nissenson. DaVita, Inc. F-PO1207

Comparative Effectiveness of Intravenous Vitamin D Agents. Carey Colson, Mahesh Krishnan, Tracy J. Mayne, Allen R. Nissenson. DaVita, Inc. F-PO1215

Hemodialysis (HD) Patients Utilizing Kidney Specialty Pharmacy Have Higher Medication Adherence, Fewer Hospitalizations and Lower Healthcare Costs. Harold Manley, Steven Wang, Allen R. Nissenson. DaVita, Inc. F-PO1507

Catheter Reduction Reduces Hospitalization and Mortality. Steve Wilson, Tracy J. Mayne, David Madigan, John Robertson, Janet Holland, Abbe Volz. DaVita, Inc. F-PO1576

Association of the Malnutrition-Inflammation Score (MIS) with First 90 Day Mortality in Incident Hemodialysis (HD) Patients. Debbie Benner, Kamyar Kalantar-Zadeh, Lilia Lukowsky, Steve Wilson, Kathy Lahr, Karen Spach, Mahesh Krishnan. DaVita, Inc. and Harold Simmons Center, Harbor-UCLA Medical Center. SA-PO2555

Focused Phosphorus Management Program Decreases Hyperphosphataemia in End Stage Renal Disease Patients. Tracy J. Mayne, Steve Wilson, Carey Colson, Kathy Ricketts. DaVita, Inc., and Shire. TH-PO155

“We are thrilled to be making such a statement at the ASN Annual Meeting with numerous presentations given by our high-caliber experts and thought leaders,” stated DCR president Chris Rucker. “We are very fortunate to have the opportunity to showcase our expertise and thought leadership. Our organization’s devotion to this industry through research is what helps us excel.”

ASN is an organization made up of more than 11,000 physicians and scientists, all committed to preventing kidney disease and making life better for patients. ASN funds research, convenes world-renowned meetings, and generates educational tools enabling nephrologists to be most effective.

As a staff fully committed to advancing the awareness and practice of kidney care, DCR brings knowledge, skill, and expertise to pharmaceutical research and clinical diagnostics, enabling the success of clinical trials and patient outcomes.

About DaVita Clinical Research
DaVita Clinical Research (DCR) is committed to advancing the knowledge and practice of kidney care. DCR brings extensive knowledge, skill, and expertise to pharmaceutical research, enabling the success of their clients’ clinical trials. Their clinical expertise ranges from designing the study to preparing and submitting the final report. DCR’s Early Clinical Research unit (Phase I-IIb) and Clinical Development network of physicians and investigative sites is focused on providing world-class clinical research in both complex/specialty populations and therapeutic areas as well as CKD and ESRD populations needed to meet clinical goals. To learn more about DCR, visit www.davitaclinicalresearch.com.

About DaVita Inc.
DaVita Inc., a Fortune 500® company, is a leading provider of kidney care in the United States, delivering dialysis services and education to patients with chronic kidney failure and end stage renal disease. As of September 30, 2010, DaVita operated or provided administrative services at 1,598 dialysis facilities, serving approximately 124,000 patients. DaVita develops, participates in and donates to numerous programs dedicated to transforming communities and creating positive, sustainable change for children, families and our environment. The company’s leadership development initiatives and corporate social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu, among others. For more information, please visit www.davita.com.



CONTACT:

DaVita, Inc.
Kelsey Rood, 310-536-2404
[email protected]

KEYWORDS:   United States  North America  Colorado  Minnesota

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Hospitals  Pharmaceutical  Diabetes  General Health  Managed Care

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.